drug · antibody drug conjugate
trastuzumab deruxtecan
Marketedupdated 3mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.
indications
investigational
NSCLCColorectal Cancer
targets
Receptor tyrosine-protein kinase erbB-2DNA topoisomerase 1
all catalysts(13)
approval · 13
Dec 20, 2019
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 15, 2021
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
May 4, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
May 4, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Aug 5, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Aug 11, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Nov 4, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Feb 15, 2024
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Apr 5, 2024
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 27, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 27, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Dec 15, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Dec 15, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Trials studying trastuzumab deruxtecan
- phase3DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- phase3A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- phase1A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- phase3Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
- phase3Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- —Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
- phase1Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
News(10)
- ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everIf AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.biospace · 8d ago
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.biospace · 12d ago
- AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesAstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.fiercebiotech · 16d ago
- ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealFor years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…fiercebiotech · 21d ago
- Merck ADC, in China study, shows potential to replace chemo in lung cancerThe results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.biopharma_dive · 27d ago
- STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and moreA U.S. appeals court revived a Teva Pharmaceuticals lawsuit accusing Eli Lilly of breaching an agreement allowing Teva to market a generic version of Forteostat · 28d ago
- STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patentsA group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences over patents for HIV prevention.stat · 29d ago
- STAT+: Pharmalittle: We’re reading about an RFK Jr. push against psychiatric meds, a Sanofi blood cancer drug, and moreU.S. health secretary Robert F. Kennedy Jr. is pressing forward with his effort to help Americans stop taking SSRI antidepressantsstat · 29d ago
- STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and moreGerman lawmakers passed a bill that would more than double the discount on branded medicines drugmakers must provide the governmentstat · 1mo ago
- STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and moreThe White House is reviewing a list of three top contenders for the FDA commissioner poststat · 1mo ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that